Randomized Controlled Trial of Rituximab and Cost‐Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's SyndromeSimon Bowman, Colin Everett, John O’Dwyer et al.|Arthritis & Rheumatology|2017Cited by 269
The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositisAlexander Oldroyd, Dennis McGonagle, Jamie C. Sergeant et al.|Lara D. Veeken|2018Cited by 110
Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudyBenjamin A. Fisher, Simon Bowman, Colin Everett et al.|Annals of the Rheumatic Diseases|2017Cited by 109
Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics RegisterEoghan McCarthy, Emily Sutton, Stephanie Nesbit et al.|Lara D. Veeken|2017Cited by 94
Soluble molecule profiling and network analysis of primary Sjögren's Syndrome patient serumJ Tarn, Wan‐Fai Ng, A Natasari et al.|BMC Musculoskeletal Disorders|2013Cited by 35